First In Human Study of CX-2051 in Advanced Solid Tumors

Inclusion Criteria

• Metastatic or locally advanced unresectable solid tumor that has progressed after standard therapy
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
• Measurable disease per RECIST v1.1
• Consent to fresh biopsy or if medically contraindicated, recent (within 6 months) archival tumor tissue
• Additional inclusion criteria may apply

Exclusion Criteria

• Recent history (within last 2 years) of localized cancers that are not related to the current cancer being treated
• Known active central nervous system (CNS) involvement by malignancy
• Systemic anticancer treatment, radiotherapy, or investigational agent(s) within 14 days prior to C1D1
• Previous treatment with antibody-drug conjugates (ADCs) with Topo-I inhibitor payload
• Major surgery (requiring general anesthesia) within 4 weeks prior to C1D1
• Elevated baseline laboratory values
• Serious concurrent illness
• Pregnant or breast feeding
• Additional exclusion criteria may apply